
    
      The study design will include: 1) up to a 2-week Screening Period (screening should be
      complete within 2 weeks prior to Week -4), 2) a 4-week MTX Run in Period (Week - 4 through
      Day 1); 3) a 52-week Pegloticase + IMM (immunomodulator), (Pegloticase + MTX) Period 4) a
      Safety Follow-up (Phone/Email/Site Visit) and 5) a 3 and 6 month Post Treatment Follow-up.
    
  